• Smart Microchips in Human Organs: A Biomedical Approach to Early Detection and Prevention of Cancer
  • Mohammad Mehdipour,1,*
    1. ORCID ID:0009-0005-4794-2040/Comprehensive Helath Research Center,Bab.Co,Islamic Azad University,Babol,Iran


  • Introduction: In recent decades, biomedical engineering has witnessed transformative progress through the development of smart microchip technologies that are reshaping the way diseases are diagnosed, monitored, and treated. One of the most promising applications of these innovations lies in the early detection and prevention of cancer, which remains one of the leading causes of death globally. This paper provides a comprehensive review of the latest advancements in wearable and implantable biochips, organ-on-chip (OOC) systems, and innovations in microfluidic technologies integrated with biosensors, nanomaterials, and artificial intelligence (AI).
  • Methods: This study reviews and analyzes the following categories of technologies: Wearable and implantable chips: Including skin-mounted sensors, smart textiles, and subcutaneous or intra-organ devices capable of continuously monitoring vital parameters such as glucose levels, blood pressure, and cancer-related biomarkers. These systems use biocompatible nanomaterials and self-powered mechanisms to ensure accuracy, long-term stability, and patient safety. Biosensing microchips: Designed to detect molecular biomarkers such as miRNAs, DNA, and proteins with high specificity and sensitivity. These devices support early cancer diagnosis, treatment monitoring, and the development of personalized therapies. Microfluidic and lab-on-a-chip systems: Allow precise control of fluid samples at the microscale, enabling compact, cost-effective diagnostic platforms that require minimal sample volumes and deliver rapid results. Organ-on-a-chip (OOC) platforms: Miniaturized systems that simulate the structural and functional behaviors of human organs (e.g., heart, liver, lungs). These tools are used for disease modeling, drug testing, and evaluating cancer cell responses in physiologically relevant conditions. Integration with AI and machine learning: Facilitates real-time data analysis, predictive diagnostics, and decision-making tailored to individual patients.
  • Results: Key findings from the review include: Wearable and implantable biosensors have demonstrated strong potential for real-time, continuous health monitoring, enabling early detection of cancer through biomarker analysis. Microfluidic lab-on-a-chip technologies have significantly reduced the cost and time required for diagnostic testing while increasing portability and automation. Organ-on-chip models provide physiologically accurate platforms for studying tumor behavior, simulating organ-level responses, and testing drug efficacy with fewer ethical and financial constraints compared to traditional animal testing. • The integration of AI has improved the interpretation of complex biological data and supports more accurate and timely clinical decision-making.
  • Conclusion: Despite the significant promise, several challenges hinder widespread clinical adoption. These include: Long-term biocompatibility of implantable devices Sustainable power sources for continuous operation Lack of international standards and regulatory frameworks Concerns about data privacy and cybersecurity The complexity of real-time data analysis from wearable systems Nevertheless, the future outlook is highly positive. The convergence of cutting-edge technologies—such as body-on-a-chip systems, next-generation biocompatible materials, and innovative commercial solutions like the "InBlood" chip—combined with multi-channel distribution strategies and global collaboration, is expected to accelerate mainstream adoption. These innovations hold the potential to: Improve early diagnosis and therapeutic outcomes Reduce healthcare costs Support a transition toward personalized, preventive, and proactive medicine The application of smart microchips in biomedical science, especially in the field of cancer diagnostics, represents a fundamental shift in how healthcare is delivered—moving from reactive treatments to precision-based interventions tailored to individual needs.
  • Keywords: Smart Microchips, Wearable Devices, Implantable Biosensors, Microfluidics, Organ-on-a-Chip, Cancer D